Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
With enzalutamide (Xtandi) and apalutamide (Erleada) already available for the treatment of these patients, the bar was set high, and darolutamide clearly met this bar in terms of activity, Posadas says.
Darolutamide is a very different molecule, which lacks penetration of the central nervous system, and so far data support that this results in reduced toxicity. Posadas says it will be interesting to see how toxicity is impacted as more data become available.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More